Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S. Uchibori K, et al. Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23. Lung Cancer. 2018. PMID: 30268482 Clinical Trial.
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, Nishio M, Katayama R. Ariyasu R, et al. Among authors: uchibori k. Lung Cancer. 2018 Mar;117:1-6. doi: 10.1016/j.lungcan.2017.12.018. Epub 2018 Jan 4. Lung Cancer. 2018. PMID: 29496249
Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.
Saiki M, Kitazono S, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Yanagitani N, Horiike A, Ohyanagi F, Oikado K, Ninomiya H, Takeuchi K, Ishikawa Y, Nishio M. Saiki M, et al. Among authors: uchibori k. Clin Lung Cancer. 2018 Sep;19(5):435-440.e1. doi: 10.1016/j.cllc.2018.04.006. Epub 2018 May 10. Clin Lung Cancer. 2018. PMID: 29885946
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M. Takano N, et al. Among authors: uchibori k. Lung Cancer. 2019 May;131:69-77. doi: 10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21. Lung Cancer. 2019. PMID: 31027701
Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.
Kitazono S, Sakai K, Yanagitani N, Ariyasu R, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Uchibori K, Horiike A, Nishio K, Nishio M. Kitazono S, et al. Among authors: uchibori k. Cancer Sci. 2019 Oct;110(10):3350-3357. doi: 10.1111/cas.14153. Epub 2019 Aug 19. Cancer Sci. 2019. PMID: 31361375 Free PMC article.
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.
Hasegawa T, Yanagitani N, Utsumi H, Wakui H, Sakamoto H, Tozuka T, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Uchibori K, Kitazono S, Horiike A, Horai T, Kuwano K, Nishio M. Hasegawa T, et al. Among authors: uchibori k. Anticancer Res. 2019 Dec;39(12):6851-6857. doi: 10.21873/anticanres.13902. Anticancer Res. 2019. PMID: 31810952
59 results